Search the Marketing Knowledge Center

Reset Search

Narrow Your Search

Date Range

Topics

Industries

Regions

Products

Archived Content

Search terms:   
 All Words    Any Words    Exact Phrase   Sort by: 

Search returned: 22 document(s).

12 >>

The Legislative Climate in D.C. and the Implications for Pharma

Trends in Washington that will affect the pharmaceutical industry include tax reform proposals and privacy concerns.

Social Media Risks and Rewards for Pharma

An overview of the regulatory landscape across social media for pharmaceutical companies.

Award-Winning Case Study: ZYRTEC’s "Muddle No More”

ZYRTEC shared an award-winning case study on gaining share and differentiation on a challenger budget.

2013 Lessons Learned and 2014 Practical Tips

There were significant changes in almost every aspect of the law relating to advertising, marketing and promotions in 2013. Davis & Gilbert LLP explains what happened and offers suggestions for advertisers and agencies to think about and address in 2014.

FDA Proposes to Ease Rules for Pharmaceutical Ads on Social Media

Recently, the Food and Drug Administration issued a draft guidance that proposes to make advertising prescription products on social media less burdensome. Comments are due on the FDA’s draft guidance within ninety days.

Venable LLP: More Muscle Behind Fitness Consent Decrees

In this advertising alert Venable LLP discusses recent fitness consent decrees regarding the new level of substantiation that the Federal Trade Commission (FTC) requires marketers to produce in support of products which make claims for wellness, weight-loss, or slimming.

Washington Update

Dan Jaffe, group EVP, government relations, ANA, discussed the latest issues in Washington regarding ad taxes, food advertising to children, ICANN’s proposed top-level domain (TLD) program, and online piracy best practices.

Pharmaceutical Marketing

This Kantar Media-sponsored article from Ad Age looks at the challenges and impending transitions facing the pharmaceutical industry.

2011 Compendium of Legislative, Regulatory, and Legal Issues

This document outlines the advocacy efforts of our Government Relations team in 2011.

Update on Legislative and Regulatory Issues

Dan Jaffe, EVP, government relations, ANA, provided updates on a number of issues including the national debt ceiling, tax reform, self-regulation, and ICANN.

Marketing Moratorium: The Pharmaceutical Industry and D.C.

Dan Jaffe, EVP, government relations, ANA, discussed legal and regulatory issues that may impact the pharmaceutical industry.

Making Mobile Happen in Pharmaceutical Marketing

Jose Cornejo, Mobile Health, Augme Tech, and Michelle Monte, account supervisor, Augme Mobile Health, Augme Tech, discussed how pharmaceutical companies can get involved in the mobile space.

Social Media: Opportunities and Challenges for the Pharmaceutical Industry

Keri S. Bruce, associate, ReedSmith, discussed the challenges facing pharmaceutical companies that are trying to enter the world of social media.

Washington and the Internet: Does Washington Want the Truth? (Welcome to the Bully Pulpit)

Douglas J. Wood, partner, Reed Smith, LLC, discussed the current hurdles, government regulations, risks, and best practices for marketers in relation to digital media and the internet.

Washington and the Internet: Does Washington Want the Truth? (Welcome to the Bully Pulpit)

Douglas J. Wood, partner, Reed Smith, LLC, discussed the current hurdles, government regulations, risks, and best practices for marketers in relation to digital media and the internet.

Regulation of the Promotion of Prescription Drugs (DDMAC Update)

Watch Bryant Godfrey, Regulatory Counsel, Division of Drug Marketing, Advertising and Communications, Food and Drug Administration discuss what is called a “risk-based” approach to enforcing the FDA’s regulatory policies.

Regulation of the Promotion of Prescription Drugs (DDMAC Update)

Bryant Godfrey, regulatory counsel, Division of Drug Marketing, Advertising and Communications, Food and Drug Administration, provided an update on what areas the agency is currently focusing on and how they may impact the advertising industry.

Pharmaceutical Marketing: Navigating the Complex Waters

Dan Jaffe, executive vice president, government relations at ANA, and Bruce Grant, senior vice president, business strategy at Digitas Health, discussed how federal legislation and social media are impacting pharmaceutical marketing.

Legislative and Regulatory Update

Dan Jaffe, EVP, government relations, ANA, provided a legislative and regulatory update, covering issues relating to financial reform legislation, privacy policies, the new Supreme Court vacancy, and the FTC's attempts to gain more rulemaking authority.

The FDA and Advertising

Joshua M. Sharfstein, principal deputy commissioner, Food and Drug Administration (FDA), shared his thoughts on how advertisers can work together with the FDA to improve public health.

12 >>